{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:48:56Z","timestamp":1762508936926},"reference-count":50,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,11]]},"DOI":"10.7759\/cureus.33648","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T14:01:01Z","timestamp":1673445661000},"source":"Crossref","is-referenced-by-count":9,"title":["The Benefits Outweigh the Risks of Treating Hypercholesterolemia: The Statin Dilemma"],"prefix":"10.7759","author":[{"given":"Azhar","family":"Hussain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasndeep","family":"Kaler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sidhartha D","family":"Ray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Heart disease facts. (2022). Accessed. October 21, 2022: https:\/\/www.cdc.gov\/heartdisease\/facts.htm."},{"key":"ref2","unstructured":"Heart disease and stroke. (2022). Accessed. October 22, 2022: https:\/\/www.cdc.gov\/chronicdisease\/resources\/publications\/factsheets\/heart-disease-stroke.htm."},{"key":"ref3","unstructured":"HDL (good), LDL (bad) cholesterol and triglycerides. (2020). Accessed. October 22, 2022: https:\/\/www.heart.org\/en\/health-topics\/cholesterol\/hdl-good-ldl-bad-cholesterol-and-triglycerides."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.6515\/acs20160611a","article-title":"Statin therapy: Review of safety and potential side effects","volume":"32","author":"Ramkumar S","year":"2016","unstructured":"Ramkumar S, Raghunath A, Raghunath S. Statin therapy: Review of safety and potential side effects. Acta Cardiol Sin. 2016, 32:631-9. 10.6515\/acs20160611a","journal-title":"Acta Cardiol Sin"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2165\/0129784-200808060-00004","article-title":"Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism","volume":"8","author":"Golomb BA","year":"2008","unstructured":"Golomb BA, Evans MA. Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs. 2008, 8:373-418. 10.2165\/0129784-200808060-00004","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2007.03.016","article-title":"Mevalonate pathway: a review of clinical and therapeutical implications","volume":"40","author":"Buhaescu I","year":"2007","unstructured":"Buhaescu I, Izzedine H. Mevalonate pathway: a review of clinical and therapeutical implications. Clin Biochem. 2007, 40:575-84. 10.1016\/j.clinbiochem.2007.03.016","journal-title":"Clin Biochem"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2017.11.030","article-title":"Statins: pros and cons","volume":"150","author":"Pinal-Fernandez I","year":"2018","unstructured":"Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Statins: pros and cons. Med Clin (Barc). 2018, 150:398-402. 10.1016\/j.medcli.2017.11.030","journal-title":"Med Clin (Barc)"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acc.2015.10.005","article-title":"Biochemistry of statins","volume":"73","author":"Egom EE","year":"2016","unstructured":"Egom EE, Hafeez H. Biochemistry of statins. Adv Clin Chem. 2016, 73:127-68. 10.1016\/bs.acc.2015.10.005","journal-title":"Adv Clin Chem"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e318282ab8f","article-title":"Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association","volume":"127","author":"Go AS","year":"2013","unstructured":"Go AS, Mozaffarian D, Roger VL, et al.. Executive summary: heart disease and stroke statistics--2013 update: a report from the American Heart Association. Circulation. 2013, 127:143-52. 10.1161\/CIR.0b013e318282ab8f","journal-title":"Circulation"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.130300","article-title":"Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase","volume":"144","author":"Istvan ES","year":"2002","unstructured":"Istvan ES. Structural mechanism for statin inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Am Heart J. 2002, 144:S27-32. 10.1067\/mhj.2002.130300","journal-title":"Am Heart J"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.4.462","article-title":"Adherence with statin therapy in elderly patients with and without acute coronary syndromes","volume":"288","author":"Jackevicius CA","year":"2002","unstructured":"Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002, 288:462-7. 10.1001\/jama.288.4.462","journal-title":"JAMA"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4330\/wjc.v7.i7.404","article-title":"Cholesterol confusion and statin controversy","volume":"7","author":"DuBroff R","year":"2015","unstructured":"DuBroff R, de Lorgeril M. Cholesterol confusion and statin controversy. World J Cardiol. 2015, 7:404-9. 10.4330\/wjc.v7.i7.404","journal-title":"World J Cardiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-019-06904-x","article-title":"State of the art comprehensive review of individual statins, their differences, pharmacology, and clinical implications","volume":"33","author":"Azemawah V","year":"2019","unstructured":"Azemawah V, Movahed MR, Centuori P, et al.. State of the art comprehensive review of individual statins, their differences, pharmacology, and clinical implications. Cardiovasc Drugs Ther. 2019, 33:625-39. 10.1007\/s10557-019-06904-x","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.687585","article-title":"Hydrophilic or lipophilic statins?","volume":"8","author":"Climent E","year":"2021","unstructured":"Climent E, Benaiges D, Pedro-Botet J. Hydrophilic or lipophilic statins?. Front Cardiovasc Med. 2021, 8:687585. 10.3389\/fcvm.2021.687585","journal-title":"Front Cardiovasc Med"},{"key":"ref15","article-title":"Pharmacological aspects of statins are relevant to their structural and physicochemical properties","volume":"11","author":"Althanoon Z","year":"2020","unstructured":"Althanoon Z, Faisal IM, Ahmad AA, et al.. Pharmacological aspects of statins are relevant to their structural and physicochemical properties. Sys Rev Pharm. 2020, 11:167-171.","journal-title":"Sys Rev Pharm"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar N","year":"2010","unstructured":"Sattar N, Preiss D, Murray HM, et al.. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010, 375:735-742. 10.1016\/S0140-6736(09)61965-6","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2014.02.014","article-title":"Statin treatment and new-onset diabetes: a review of proposed mechanisms","volume":"63","author":"Brault M","year":"2014","unstructured":"Brault M, Ray J, Gomez YH, Mantzoros CS, Daskalopoulou SS. Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism. 2014, 63:735-45. 10.1016\/j.metabol.2014.02.014","journal-title":"Metabolism"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2610","article-title":"Risk of incident diabetes among patients treated with statins: population based study","volume":"346","author":"Carter AA","year":"2013","unstructured":"Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013, 346:f2610. 10.1136\/bmj.f2610","journal-title":"BMJ"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-006-0269-5","article-title":"Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control","volume":"49","author":"Nakata M","year":"2006","unstructured":"Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia. 2006, 49:1881-92. 10.1007\/s00125-006-0269-5","journal-title":"Diabetologia"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702397","article-title":"Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells","volume":"126","author":"Yada T","year":"1999","unstructured":"Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol. 1999, 126:1205-13. 10.1038\/sj.bjp.0702397","journal-title":"Br J Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.fp0072403","article-title":"Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes","volume":"107","author":"Takaguri A","year":"2008","unstructured":"Takaguri A, Satoh K, Itagaki M, Tokumitsu Y, Ichihara K. Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes. J Pharmacol Sci. 2008, 107:80-9. 10.1254\/jphs.fp0072403","journal-title":"J Pharmacol Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1210\/en.2008-0161","article-title":"Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells","volume":"149","author":"Xia F","year":"2008","unstructured":"Xia F, Xie L, Mihic A, Gao X, Chen Y, Gaisano HY, Tsushima RG. Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells. Endocrinology. 2008, 149:5136-45. 10.1210\/en.2008-0161","journal-title":"Endocrinology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2012.12.037","article-title":"Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus","volume":"111","author":"Navarese EP","year":"2013","unstructured":"Navarese EP, Buffon A, Andreotti F, et al.. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol. 2013, 111:1123-30. 10.1016\/j.amjcard.2012.12.037","journal-title":"Am J Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-007-0050-3","article-title":"Statin myopathy: incidence, risk factors, and pathophysiology","volume":"9","author":"Sewright KA","year":"2007","unstructured":"Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep. 2007, 9:389-96. 10.1007\/s11883-007-0050-3","journal-title":"Curr Atheroscler Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-007-0060-8","article-title":"Rhabdomyolysis","volume":"2","author":"Bagley WH","year":"2007","unstructured":"Bagley WH, Yang H, Shah KH. Rhabdomyolysis. Intern Emerg Med. 2007, 2:210-8. 10.1007\/s11739-007-0060-8","journal-title":"Intern Emerg Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1993.tb03948.x","article-title":"Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study","volume":"33","author":"Ghirlanda G","year":"1993","unstructured":"Ghirlanda G, Oradei A, Manto A, et al.. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol. 1993, 33:226-9. 10.1002\/j.1552-4604.1993.tb03948.x","journal-title":"J Clin Pharmacol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-12-200906160-00009","article-title":"Narrative review: statin-related myopathy","volume":"150","author":"Joy TR","year":"2009","unstructured":"Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009, 150:858-68. 10.7326\/0003-4819-150-12-200906160-00009","journal-title":"Ann Intern Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/s1734-1140(11)70601-6","article-title":"Statin-induced myopathies","volume":"63","author":"Tomaszewski M","year":"2011","unstructured":"Tomaszewski M, St\u0119pie\u0144 KM, Tomaszewska J, Czuczwar SJ. Statin-induced myopathies. Pharmacol Rep. 2011, 63:859-866. 10.1016\/s1734-1140(11)70601-6","journal-title":"Pharmacol Rep"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00226.2006","article-title":"Statin-induced apoptosis and skeletal myopathy","volume":"291","author":"Dirks AJ","year":"2006","unstructured":"Dirks AJ, Jones KM. Statin-induced apoptosis and skeletal myopathy. Am J Physiol Cell Physiol. 2006, 291:C1208-12. 10.1152\/ajpcell.00226.2006","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-003-0008-z","article-title":"Isoprenoid metabolism and the pleiotropic effects of statins","volume":"5","author":"Laufs U","year":"2003","unstructured":"Laufs U, Liao JK. Isoprenoid metabolism and the pleiotropic effects of statins. Curr Atheroscler Rep. 2003, 5:372-8. 10.1007\/s11883-003-0008-z","journal-title":"Curr Atheroscler Rep"},{"key":"ref31","article-title":"Statins rise cytoplasmic calcium level [Ca2+]i in cultured endothelial cells","volume":"56","author":"Lorkowska B","year":"2004","unstructured":"Lorkowska B, Chlopicki S, Marcinkiewicz E, Gryglewski RJ. Statins rise cytoplasmic calcium level [Ca2+]i in cultured endothelial cells. Pol J Pharmacol. 2004, 56:313-8.","journal-title":"Pol J Pharmacol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.tcm.2004.06.003","article-title":"Regulation of ryanodine receptors by FK506 binding proteins","volume":"14","author":"Chelu MG","year":"2004","unstructured":"Chelu MG, Danila CI, Gilman CP, Hamilton SL. Regulation of ryanodine receptors by FK506 binding proteins. Trends Cardiovasc Med. 2004, 14:227-34. 10.1016\/j.tcm.2004.06.003","journal-title":"Trends Cardiovasc Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2007.12.010","article-title":"New insights into mechanisms of statin-associated myotoxicity","volume":"8","author":"Sirvent P","year":"2008","unstructured":"Sirvent P, Mercier J, Lacampagne A. New insights into mechanisms of statin-associated myotoxicity. Curr Opin Pharmacol. 2008, 8:333-8. 10.1016\/j.coph.2007.12.010","journal-title":"Curr Opin Pharmacol"},{"key":"ref34","doi-asserted-by":"crossref","DOI":"10.2174\/1874259900802010018","article-title":"Statins: hepatic disease and hepatotoxicity risk","volume":"2","author":"Cueto R","year":"2008","unstructured":"Cueto R, Valdivielso P, Lucena MI, Garc\u00eda-Arias C, Andrade RJ, Gonz\u00e1lez-Santos P. Statins: hepatic disease and hepatotoxicity risk. Open Gastroenterol J. 2008, 2:18-23.","journal-title":"Open Gastroenterol J"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1002\/cld.866","article-title":"Use of statins in patients with and without liver disease","volume":"15","author":"Francis P","year":"2020","unstructured":"Francis P, Forman L. Use of statins in patients with and without liver disease. Clin Liver Dis (Hoboken). 2020, 15:40-5. 10.1002\/cld.866","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"ref36","article-title":"Statins and liver injury","volume":"9","author":"Thapar M","year":"2013","unstructured":"Thapar M, Russo MW, Bonkovsky HL. Statins and liver injury. Gastroenterol Hepatol (NY). 2013, 9:605-606.","journal-title":"Gastroenterol Hepatol (NY)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12461","article-title":"The role of mitochondria in statin-induced myopathy","volume":"45","author":"Apostolopoulou M","year":"2015","unstructured":"Apostolopoulou M, Corsini A, Roden M. The role of mitochondria in statin-induced myopathy. Eur J Clin Invest. 2015, 45:745-54. 10.1111\/eci.12461","journal-title":"Eur J Clin Invest"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12654","article-title":"Effects of statins on mitochondrial pathways","volume":"12","author":"Mollazadeh H","year":"2021","unstructured":"Mollazadeh H, Tavana E, Fanni G, et al.. Effects of statins on mitochondrial pathways. J Cachexia Sarcopenia Muscle. 2021, 12:237-51. 10.1002\/jcsm.12654","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.3390\/jcm6080075","article-title":"Statins, muscle disease and mitochondria","volume":"6","author":"Ramachandran R","year":"2017","unstructured":"Ramachandran R, Wierzbicki AS. Statins, muscle disease and mitochondria. J Clin Med. 2017, 6:10.3390\/jcm6080075","journal-title":"J Clin Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/ijms160716067","article-title":"Mevalonate pathway blockade, mitochondrial dysfunction and autophagy: a possible link","volume":"16","author":"Tricarico PM","year":"2015","unstructured":"Tricarico PM, Crovella S, Celsi F. Mevalonate pathway blockade, mitochondrial dysfunction and autophagy: a possible link. Int J Mol Sci. 2015, 16:16067-84. 10.3390\/ijms160716067","journal-title":"Int J Mol Sci"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2007.05.013","article-title":"Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: a possible role in statin-induced hepatotoxicity?","volume":"223","author":"Tavintharan S","year":"2007","unstructured":"Tavintharan S, Ong CN, Jeyaseelan K, Sivakumar M, Lim SC, Sum CF. Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: a possible role in statin-induced hepatotoxicity?. Toxicol Appl Pharmacol. 2007, 223:173-9. 10.1016\/j.taap.2007.05.013","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3390\/ijms141223274","article-title":"Mevalonate kinase deficiency and neuroinflammation: balance between apoptosis and pyroptosis","volume":"14","author":"Tricarico PM","year":"2013","unstructured":"Tricarico PM, Marcuzzi A, Piscianz E, Monasta L, Crovella S, Kleiner G. Mevalonate kinase deficiency and neuroinflammation: balance between apoptosis and pyroptosis. Int J Mol Sci. 2013, 14:23274-88. 10.3390\/ijms141223274","journal-title":"Int J Mol Sci"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips PS","year":"2002","unstructured":"Phillips PS, Haas RH, Bannykh S, et al.. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002, 137:581-5. 10.7326\/0003-4819-137-7-200210010-00009","journal-title":"Ann Intern Med"},{"key":"ref44","article-title":"[Statins and mitochondria]","volume":"62","author":"Broniarek I","year":"2016","unstructured":"Broniarek I, Jarmuszkiewicz W. [Statins and mitochondria]. Postepy Biochem. 2016, 62:77-84.","journal-title":"Postepy Biochem"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.2337\/dcS15-3022","article-title":"Remembering statins: do statins have adverse cognitive effects?","volume":"39 Suppl 2","author":"Bitzur R","year":"2016","unstructured":"Bitzur R. Remembering statins: do statins have adverse cognitive effects?. Diabetes Care. 2016, 39 Suppl 2:S253-9. 10.2337\/dcS15-3022","journal-title":"Diabetes Care"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000333215.93440.36","article-title":"Brain cholesterol metabolism and neurologic disease","volume":"71","author":"Benarroch EE","year":"2008","unstructured":"Benarroch EE. Brain cholesterol metabolism and neurologic disease. Neurology. 2008, 71:1368-73. 10.1212\/01.wnl.0000333215.93440.36","journal-title":"Neurology"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1002\/glia.20422","article-title":"Statins induce differentiation and cell death in neurons and astroglia","volume":"55","author":"M\u00e4rz P","year":"2007","unstructured":"M\u00e4rz P, Otten U, Miserez AR. Statins induce differentiation and cell death in neurons and astroglia. Glia. 2007, 55:1-12. 10.1002\/glia.20422","journal-title":"Glia"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-021-00758-x","article-title":"Simvastatin impairs hippocampal synaptic plasticity and cognitive function in mice","volume":"14","author":"Guo Y","year":"2021","unstructured":"Guo Y, Zou G, Qi K, Jin J, Yao L, Pan Y, Xiong W. Simvastatin impairs hippocampal synaptic plasticity and cognitive function in mice. Mol Brain. 2021, 14:41. 10.1186\/s13041-021-00758-x","journal-title":"Mol Brain"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s40800-015-0024-2","article-title":"Mood, personality, and behavior changes during treatment with statins: a case series","volume":"3","author":"Cham S","year":"2016","unstructured":"Cham S, Koslik HJ, Golomb BA. Mood, personality, and behavior changes during treatment with statins: a case series. Drug Saf Case Rep. 2016, 3:1. 10.1007\/s40800-015-0024-2","journal-title":"Drug Saf Case Rep"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-128-6-199803150-00009","article-title":"Cholesterol and violence: is there a connection?","volume":"128","author":"Golomb BA","year":"1998","unstructured":"Golomb BA. Cholesterol and violence: is there a connection?. Ann Intern Med. 1998, 128:478-87. 10.7326\/0003-4819-128-6-199803150-00009","journal-title":"Ann Intern Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/129496-the-benefits-outweigh-the-risks-of-treating-hypercholesterolemia-the-statin-dilemma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:55:50Z","timestamp":1707508550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/129496-the-benefits-outweigh-the-risks-of-treating-hypercholesterolemia-the-statin-dilemma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,11]]},"references-count":50,"URL":"https:\/\/doi.org\/10.7759\/cureus.33648","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1,11]]}}}